This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights Salesforce, BP, The Southern, PayPal and Edwards Lifesciences
by Zacks Equity Research
Salesforce, BP, The Southern, PayPal and Edwards Lifesciences are included in this Analyst Blog.
Top Analyst Reports for Salesforce, BP & Southern Co.
by Mark Vickery
Toda's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), BP p.l.c. (BP) and The Southern Company (SO).
ALC vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALC vs. EW: Which Stock Is the Better Value Option?
Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have performed compared to their sector so far this year.
Down -10.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Edwards Lifesciences (EW)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Edwards Lifesciences (EW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Investing in Edwards Lifesciences (EW)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Explore how Edwards Lifesciences' (EW) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
by Zacks Equity Research
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.13% and 1.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
by Urmimala Biswas
Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.
Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings
by Zacks Equity Research
Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Unveiling Edwards Lifesciences (EW) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q1 results are expected to be aided by growing patient volumes and surgical cases, partly offset by increased expenses.
Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth
by Zacks Equity Research
Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.
Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?
by Zacks Equity Research
Humana's (HUM) first-quarter results are likely to reflect rising premiums and investment income.
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
by Nalak Das
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
Will High Medical Care Ratios Hurt Molina's (MOH) Q1 Earnings?
by Zacks Equity Research
Molina's (MOH) first-quarter performance is likely to have been hurt by escalating medical care costs, partly offset by growing membership in all three businesses.
Will Low Patient Days Impact Community Health (CYH) Q1 Earnings?
by Zacks Equity Research
Community Health's (CYH) first-quarter results are likely to reflect declining beds in services and adjusted admissions.
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
by Zacks Equity Research
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.